drugset
drugset / Trial / NCT05210868

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT05210868 ↗

Phase 1/2 Active not recruiting 184 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL

Timeline

Start
2021-11-16
Primary completion
2026-12-28
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CM355 Unknown — —

Indications

No indication recorded.